Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$8 Mln
P/E Ratio
0.89
P/B Ratio
0.2
Industry P/E
36.76
Debt to Equity
0
ROE
0.43 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-35.35 Mln
EBITDA
$-75.53 Mln
Net Profit
$-75.30 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
PharmaCyte Biotech Inc (PMCB)
| -22.29 | -22.29 | -25.15 | -44.55 | -17.21 | -50.07 | -41.21 |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
PharmaCyte Biotech Inc (PMCB)
| -27.13 | -26.28 | 17.20 | -75.13 | -83.46 | 9.46 | -33.54 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 12.99 | 618.96 | -- | -110.64 |
PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation... technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada. Address: 3960 Howard Hughes Parkway, Las Vegas, NV, United States, 89169 Read more
Interim CEO, President & Director
Mr. Joshua N. Silverman
Interim CEO, President & Director
Mr. Joshua N. Silverman
Headquarters
Las Vegas, NV
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of PharmaCyte Biotech Inc (PMCB) stood at $ 45 Mln as on 31-Jan-25
The share price of PharmaCyte Biotech Inc (PMCB) is $1.22 (NASDAQ) as of 25-Apr-2025 16:00 EDT. PharmaCyte Biotech Inc (PMCB) has given a return of -17.21% in the last 3 years.
PharmaCyte Biotech Inc (PMCB) has a market capitalisation of $ 8 Mln as on 24-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of PharmaCyte Biotech Inc (PMCB) is 0.20 times as on 24-Apr-2025, a 96% discount to its peers’ median range of 5.04 times.
The P/E ratio of PharmaCyte Biotech Inc (PMCB) is 0.89 times as on 24-Apr-2025, a 98% discount to its peers’ median range of 36.76 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the PharmaCyte Biotech Inc (PMCB) and enter the required number of quantities and click on buy to purchase the shares of PharmaCyte Biotech Inc (PMCB).
PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada. Address: 3960 Howard Hughes Parkway, Las Vegas, NV, United States, 89169
The CEO & director of Mr. Joshua N. Silverman. is PharmaCyte Biotech Inc (PMCB), and CFO & Sr. VP is Mr. Joshua N. Silverman.
There is no promoter pledging in PharmaCyte Biotech Inc (PMCB).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
62
|
| PharmaCyte Biotech Inc (PMCB) | Ratios |
|---|---|
|
Return on equity(%)
|
43.42
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of PharmaCyte Biotech Inc (PMCB) was $0 Mln.
$0.01
(
